<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00224458</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-164-0107</org_study_id>
    <nct_id>NCT00224458</nct_id>
  </id_info>
  <brief_title>Combination of Efavirenz and Truvada - COMET Study</brief_title>
  <official_title>Combination of Efavirenz &amp; Truvada (COMET Study): Phase 4 Evaluation of Switching Twice Daily Combivir to Once-Daily Regimen Co-Formulated Truvada in Virologically Suppressed HIV Infected Patients Taking Efavirenz.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      To characterize the risks (safety and tolerability), effectiveness (continued viral load&#xD;
      suppression and CD4 changes), and benefits (safety, tolerability, adherence, general&#xD;
      satisfaction with the treatment regimen and QoL), of switching from a Combivir (BID) /&#xD;
      efavirenz (QD) regimen to an all QD regimen of Truvada/efavirenz.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to characterize the risks (safety and tolerability),&#xD;
      effectiveness (continued viral load suppression and CD4 changes), and benefits (safety,&#xD;
      tolerability, adherence, general satisfaction with the treatment regimen and QoL), of&#xD;
      switching from a Combivir (BID) / efavirenz (QD) regimen to an all QD regimen of&#xD;
      Truvada/efavirenz.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the risks (safety and tolerability), effectiveness (continued viral load suppression and CD4 changes), and benefits (safety, tolerability, adherence, general satisfaction with the treatment regimen and QoL)</measure>
  </primary_outcome>
  <enrollment>400</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (greater than 18 years) male or non-pregnant female HIV-1 infected patients&#xD;
             regardless of race or ethnicity.&#xD;
&#xD;
          -  On a stable antiretroviral regimen consisting of efavirenz QD and Combivir BID for&#xD;
             greater than 8 weeks.&#xD;
&#xD;
          -  Plasma HIV 1 RNA less than 400 copies/mL (Roche Amplicor HIV 1 Monitor Test Version&#xD;
             1.5 Ultrasensitive method).&#xD;
&#xD;
          -  Currently experiencing adverse clinical or laboratory effects associated with Combivir&#xD;
             and/or who might benefit from a simplified, once-daily antiretroviral treatment&#xD;
             regimen regardless of Combivir tolerability status.&#xD;
&#xD;
          -  Adequate renal function defined as a calculated creatinine clearance (CLCr) greater&#xD;
             than or equal to 50 mL/min according to the Cockcroft-Gault formula:&#xD;
&#xD;
        Male: (140 - age in years) x (wt in kg) divided by 72 x (serum creatinine in mg/dL) = CLCr&#xD;
        (mL/min.&#xD;
&#xD;
        Female: (140 - age in years) x(wt in kg) divided by 72 x (serum creatinine in mg/dL) x 0.85&#xD;
        = CLCr (mL/min).&#xD;
&#xD;
          -  Negative serum pregnancy test (females of childbearing potential only).&#xD;
&#xD;
          -  Willingness to use effective contraception (such as barrier or coil methods) by both&#xD;
             males and females while on study drug and for 30 days following study drug completion.&#xD;
&#xD;
          -  Life expectancy less than 1 year.&#xD;
&#xD;
          -  The ability to understand and sign a written informed consent form, which must be&#xD;
             obtained prior to initiation of any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A new AIDS defining condition diagnosed (with the exception of CD4 criteria) within 30&#xD;
             days of baseline.&#xD;
&#xD;
          -  Clinically significant laboratory values that would preclude prescribing&#xD;
             antiretroviral therapy, in the opinion of the investigator.&#xD;
&#xD;
          -  Receiving on-going therapy with any of the following (administration of any of the&#xD;
             following medications must be discontinued at least 30 days prior to the Baseline&#xD;
             visit and for the duration of the study period):&#xD;
&#xD;
          -  Nephrotoxic agents (aminoglycoside antibiotics, IV amphotericin B, cidofovir,&#xD;
             cisplatin, foscarnet, IV pentamidine, other agents with significant nephrotoxic&#xD;
             potential):&#xD;
&#xD;
               -  Adefovir dipivoxil&#xD;
&#xD;
               -  Probenecid&#xD;
&#xD;
               -  Systemic chemotherapeutic agents (i.e., cancer treatment medications)&#xD;
&#xD;
               -  Systemic corticosteroids&#xD;
&#xD;
               -  Interleukin 2 (IL 2)&#xD;
&#xD;
               -  Investigational agents (except upon approval by Gilead).&#xD;
&#xD;
          -  Drugs that interact with efavirenz:&#xD;
&#xD;
               -  dihydroergotamine&#xD;
&#xD;
               -  ergotamine&#xD;
&#xD;
               -  ergonovine&#xD;
&#xD;
               -  methylergonovine&#xD;
&#xD;
               -  midazolam&#xD;
&#xD;
               -  triazolam&#xD;
&#xD;
               -  cisapride&#xD;
&#xD;
               -  rifampin&#xD;
&#xD;
          -  Pregnant or lactating patients.&#xD;
&#xD;
          -  Evidence of a gastrointestinal malabsorption syndrome or chronic nausea or vomiting&#xD;
             which may confer an inability to receive an orally administered medication.&#xD;
&#xD;
          -  Current alcohol or substance abuse judged by the investigator to potentially interfere&#xD;
             with patient adherence.&#xD;
&#xD;
          -  Malignancy other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma.&#xD;
             Patients with biopsy-confirmed cutaneous KS are eligible, but must not have received&#xD;
             any systemic therapy for KS within 30 days of baseline and are not anticipated to&#xD;
             require systemic therapy during the study.&#xD;
&#xD;
          -  Active, serious infections (other than HIV 1 infection) requiring parenteral&#xD;
             antibiotic therapy within 15 days prior to screening.&#xD;
&#xD;
          -  Prior history of significant renal or bone disease.&#xD;
&#xD;
          -  Any other clinical condition or prior therapy that, in the opinion of the&#xD;
             investigator, would make the patient unsuitable for the study or unable to comply with&#xD;
             the dosing requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Flaherty, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <link>
    <url>http://www.gilead.com</url>
    <description>Gilead Website</description>
  </link>
  <link>
    <url>http://www.truvada.com</url>
    <description>Truvada Website</description>
  </link>
  <verification_date>February 2008</verification_date>
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2005</study_first_posted>
  <last_update_submitted>April 7, 2008</last_update_submitted>
  <last_update_submitted_qc>April 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>John Flaherty, Director, Medical Affairs</name_title>
    <organization>Gilead Sciences</organization>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <keyword>HIV-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

